Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

SoftBank weighs $30bn Allied Universal acquisition from Warburg Pincus-backed owners

SoftBank Group is considering an acquisition of Allied Universal, the US security services provider backed by private equity firm Warburg Pincus and Canadian pension investor La Caisse, in a potential transaction that could value the business at close to $30bn including debt, according to a report by Bloomberg.

SoftBank Group is mulling over a potential acquisition of Allied Universal, a US security services provider backed by Warburg Pincus and La Caisse, in a deal that could be valued at nearly $30 billion, including debt, according to Bloomberg. The proposal could potentially give Allied an equity value of up to $18 billion. The company also holds around $12 billion in publicly traded loans and bonds, as per Bloomberg data.

However, these discussions are still in their early stages, with no final decision on a transaction or its price announced. The acquisition would enable SoftBank to gain exposure to a major security services platform as founder Masayoshi Son aims to broaden the commercial application of artificial intelligence and robotics. Allied offers security personnel and specialized services across various sectors, including data centers, facilities management, and maintenance.

SoftBank is currently exploring how autonomous robots could be utilized for tasks such as patrols and event security, though scaling up to replace human security staff fully is considered a longer-term goal. This move would complement SoftBank's broader strategy in AI and robotics, such as its $5.4 billion acquisition of ABB's industrial robotics business and its investment in construction robotics company Gravis Robotics.

Written by urgent.news from Private Equity Wire's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at privateequitywire.co.uk →

More in Finance & Markets

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16…

  • VERDICT trial compares CSF disease clearance vs. symptomatic remission
  • CSF clearance group had 70% lower risk of UC complications
  • Results presented at UEG Week 2026 and published in EUG Journal

More from Monday 19 October →